Related Experiment Video
Updated: Dec 5, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Efficacy of Sovodak in the Management of Patients Co-infected with HIV/HCV
Mohammad Hossein Somi1, Bita Sepehri1, Zeinab Nikniaz1
1Liver and gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract:
Sofosbuvir (SOF) and daclatasvir (DOC) are suggested for the treatment of hepatitis C virus (HCV) in patients with concomitant HCV and human immunodeficiency virus (HIV). In 2016, Sovodak tablet a combination of SOF and DOC was introduced. In the present study we assessed the effectiveness of SOF in the treatment of HCV in patients co-infected with HIV. A total of 26 HCV patients co-infected with HIV received SOF for 3 months. One patient did not adhere to the drug protocol and was removed from the final analysis. The blood sample for qualitative polymerase chain reaction (PCR) was obtained after treatment and sustained virological response (SVR) was calculated. Twenty five patients finished the study. The mean patients' age was 44.16±6.21 years. About 72% of participants had HCV genotype 1a, 8% genotype 1b, and 20% genotype 3a. After 3 months of intervention with Sovodak, the SVR12 was about 96%. None of the patients reported any adverse events. For the first time, the results of the present study showed that Sovodak had high SVR12 in HCV patients co-infected with HIV. However, for a precise conclusion, there is a need for larger studies and an equal number of patients with different virus genotypes.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Subviral Agents
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Retroviruses
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

